top of page

Apitope regains global rights to its multiple sclerosis treatment from Merck

The drug discovery company, Apitope, has regained global rights to its compound, ATX-MS-1467, a potentially disease-modifying therapy for the treatment of multiple sclerosis (MS). Under the agreement with Merck, Apitope will regain all rights and clinical data associated with its compound ATX-MS-1467, which just completed a Phase II clinical trial.




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page